Biotech Buys

Celltech’s little deal is big news.

The final cash deal in May that decided control of Oxford GlycoSciences (OGS), a biotech firm based in the United Kingdom, was on the small side—only about $170 million from Oxford’s London neighbor, the Celltech Group. But the fact that this deal happened at all, and that at least five companies fought hard to acquire the tiny genomics-proteomics-biopharmaceutical hybrid, makes it notable.

News Analysis

Ready or Not

Vive la Differentiation!

Shrinking Staffs

Double Attack

Bull’s-Eye?

» Biotech Buys

Sniffing for SNPs